Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Finerenone (BAY94-8862): intervention A
Finerenone: intervention A · 1 trial · 2 indications
Cmax: maximum concentration.
AUC = area under the curve, which was the total amount of finerenone in plasma
| Arm | Type | Description |
|---|---|---|
| finerenone sequences: intervention A_intervention B | EXPERIMENTAL | Participants received intervention A first, with a washout period of at least 72 hours, participants then received intervention B |
| finerenone sequences: intervention B_intervention A | EXPERIMENTAL | Participants received intervention B first, with a washout period of at least 72 hours, participants then received intervention A |
| Name | Type | Description |
|---|---|---|
| Finerenone (BAY94-8862): intervention A | DRUG | Study intervention A: one tablet of dose strength 1 one tablet of dose strength 1 = two tablets of dose strength 2 |
| Finerenone (BAY94-8862): intervention B | DRUG | Study intervention B: two tablets of dose strength 2 two tablets of dose strength 2 = one tablet of dose strength 1 |
Inclusion Criteria: * Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent. * Participants who were overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, body temperature, vital signs, and E...
Finerenone: intervention A is an investigational small molecule developed by Bayer AG for heart failure with left ventricular ejection fraction greater than or equal to 40 per cent. It has been studied in a Phase 1 clinical trial in healthy male volunteers in Germany. It is not described as approved and remains in clinical development.
Finerenone: intervention A is being studied for heart failure with left ventricular ejection fraction greater than or equal to 40 per cent, a cardiovascular condition. The completed Phase 1 trial enrolled healthy male volunteers rather than patients with this condition, so the study examined drug exposure rather than clinical benefit in heart failure.
Finerenone: intervention A is developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor of the Phase 1 trial of the asset. The drug is a small molecule in the cardiovascular therapeutic area.
Finerenone: intervention A is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials of the asset are currently active. It is investigational and has not been described as approved for any indication.
Finerenone: intervention A has been studied in one completed Phase 1 trial, NCT07116512, titled a study comparing how much of the study treatment gets into the blood when the same amount is taken in one and in two tablets of different strengths. It enrolled 60 healthy male participants aged 18 years and older in Germany.
Yes, Finerenone: intervention A is also known as Finerenone (BAY94-8862): intervention A. Both names refer to the same Bayer small molecule studied in the Phase 1 trial NCT07116512 for heart failure with left ventricular ejection fraction greater than or equal to 40 per cent.